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Placebo aiTBS attenuates suicidal ideation
and frontopolar cortical perfusion in major
depression
Chris Baeken 1,2,3, Guo-Rong Wu4 and Kees van Heeringen 1
Abstract
The application of repetitive transcranial magnetic stimulation has been shown to rapidly decrease suicidal ideation in
major depressive disorder (MDD). However, the neural working mechanisms behind this prompt attenuation of
suicidal thoughts remains to be determined. Here, we examined how placebo-accelerated intermittent theta burst
stimulation (aiTBS) may inﬂuence brain perfusion and suicidal thoughts using arterial spin labeling (ASL). In a
randomized double-blind sham-controlled crossover trial, 45 MDD patients received aiTBS applied to the left
dorsolateral prefrontal cortex (Trial registration: http://clinicaltrials.gov/show/NCT01832805). With each ASL scan
measurement, suicidal ideation was assessed with the Beck Scale for Suicidal Ideation (BSI) and depression severity
with the Beck Depression Inventory (BDI). Compared with active stimulation, the attenuation of suicidal ideation after
4 days of placebo aiTBS was related to signiﬁcant frontopolar prefrontal perfusion decreases. These ﬁndings were
unrelated to changes in depression severity scores. Although both active and sham aiTBS resulted in prompt decreases
in suicidal ideation, speciﬁcally sham aiTBS signiﬁcantly attenuated frontopolar perfusion in relation to reductions in
BSI scores. Our ﬁndings show that in accelerated neurostimulation paradigms, placebo responses are related to
perfusion decreases in brain areas associated with higher cognitive processes, resulting in suicidal ideation
attenuation.
Introduction
Over the last decades, repetitive transcranial magnetic
stimulation (rTMS) has been successfully used to treat
unipolar and non-psychotic major depressive disorder
(MDD), particularly when combined with antidepressant
medication1,2. To increase response and remission rates,
intensiﬁed rTMS treatment paradigms have been intro-
duced more recently3,4. Instead of spreading rTMS ses-
sions over several weeks, a similar amount of sessions is
applied within only a few days, usually involving several
sessions per day. Such accelerated rTMS treatment pro-
tocols result not only in decreases in depressive symptoms
but also in prompt decreases of suicidal ideation5. For
instance, George et al.5 applied high-frequency rTMS
(10 Hz) to the left prefrontal cortex delivering 6.000 pul-
ses/session, three times daily for 3 days (total nine ses-
sions; 54.000 stimuli). Inpatients, who were admitted
because of suicidal ideation or a suicide attempt, were
randomized to active or sham rTMS. Trained and blinded
raters administered the Beck Suicidal Scale Inventory
(SSI6) at baseline and at the end of each day during the
3 days of treatment. After the ﬁrst day of stimulation,
active and sham rTMS were associated with a 50% and a
25% reduction in SSI scores, respectively. After comple-
tion of the intensiﬁed protocol, almost all subjects showed
substantial reductions in suicidal ideation. These ﬁndings
demonstrate that, although active stimulation in the ﬁrst
day was superior to sham, at the end of the protocol
suicidal ideation decreased comparably in both study
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groups, indicating some form of placebo response. Our
recent randomized controlled trial of accelerated inter-
mittent theta burst stimulation (aiTBS, involving bursts of
high-frequency stimulation in a short amount of time,
thus delivering the same amount of pulses as in lower
frequency protocols) showed similar rapid decreases in
suicidal ideation in MDD patients after both active and
sham stimulation7. Importantly, the attenuation of suici-
dal ideation scores was not related to changes in the
severity of depression symptoms, suggesting that aiTBS
treatment reduces suicidal ideation independently of an
improvement in depressive symptoms. These ﬁndings
thus also suggest placebo effects of TMS on suicidal
ideation, independently of its effects on the severity of
depressive symptoms.
Placebo (and nocebo) effects are well known in medi-
cine as they have been reported following many kinds of
treatments8,9. A placebo may consist of any form of
treatment or application that is used for its ameliorative
effect on a symptom or disease, but that is ineffective or
not speciﬁcally effective for the condition being treated10.
A placebo thus is not an inert substance or intervention,
but it is rather the administration of this substance or
intervention within a set of sensory and social stimuli that
inform the individual that a beneﬁcial treatment is
given11. The psychophysiological responses elicited by
placebos can be very speciﬁc depending on the provided
information, resulting in mind/body interactions that are
guided by subjective factors (e.g., expectations, beliefs,
meaning, and hope for improvement) and relational
parameters8. Placebo effects of rTMS on depressive
symptoms may appear large, but in fact are of a similar
magnitude as those of psychopharmacotherapy12. In
addition, a recent meta-analysis of rTMS studies in
depressed patients showed that the magnitude of placebo
response is associated to the effect size in the actively
treated group, suggesting that the placebo response is a
component of the therapeutic response to rTMS13.
Placebo responses (To avoid confusion on the terms
“placebo,” “placebo effect,” and “placebo response”, here
we will use the term placebo response, referring to the
outcome caused by a placebo manipulation; reﬂecting the
neurobiological and psychophysiological response to an
inert substance or sham treatment and is mediated by
various factors within the treatment context14.) are not
limited to neuropsychiatric disorders, but they have been
particularly documented in a variety of such disorders,
including chronic pain, addiction, Alzheimer’s and Par-
kinson’s disease. Such responses are usually, but not
unequivocally, associated with decreases of neural activity
involved in brain regions8,15. In general, it has been sug-
gested that placebo responses correlate with changes in a
core network of brain regions associated with the default
mode network (DMN) that is involved in self-generated
emotion, self-evaluation, thinking about the future, social
cognition, and valuation of rewards and punishment16.
Placebo responses in antidepressant medication trials
appear to correlate with functional changes in ven-
tromedial prefrontal and in posterior midline structures
(both part of the DMN) and in striatal regions9,17.
No studies have yet addressed placebo effects of non-
invasive neurostimulation on brain perfusion and suicidal
ideation in MDD patients. The current study therefore
aimed at assessing suicidal ideation and correlating brain
perfusion changes using arterial spin labeling (ASL) fMRI
before and after neurostimulation treatment in a rando-
mized sham-controlled trial in MDD patients. All patients
were at least stage I treatment-resistant according to the
Rush et al.18 criteria, meaning that they had at least one
failed treatment trial with an SSRI or SNRI. ASL fMRI
uses arterial water as an endogenous tracer to measure
cerebral blood ﬂow (CBF) and provides reliable absolute
CBF quantiﬁcations19,20. At every ASL, fMRI measure-
ment suicidal ideation and depressive symptoms were
assessed using the 21-item Beck Scale for Suicidal Idea-
tion (BSI21) and the 21-item Beck Depression Inventory
(BDI-I22).
Although active and sham accelerated paradigms both
have been shown to result in prompt attenuation of sui-
cidal ideation, we hypothesized that perfusion pattern
changes after sham aiTBS would be distinctly different
compared with those after active aiTBS treatment. We
expected brain perfusion reductions after sham aiTBS to
be present particularly in brain areas related to higher
cognitive processes, such as the DMN.
Materials and methods
Participants
The ethics committee of the Ghent University Hospital
approved this monocentric randomized double-blind
sham-controlled crossover study. The study was regis-
tered in the Clinical Trials.gov database (http://
clinicaltrials.gov/show/NCT01832805). All subjects gave
written informed consent. Inclusion criteria for the study
were (1) a major depressive disorder selected with the
Mini-International Neuropsychiatric Interview (MINI23),
(2) right-handedness, (3) at least stage I treatment-
resistance according to the Rush et al. criteria18, (4) at
least 2 weeks free from psychotropic agents (except for
the habitual use of benzodiazepines if necessary).
In total, 50 patients were included, and data on 45
patients (33 females) with the complete set of three ASL
scans were included in the analyses (see Fig. 1). The full
behavioral data were published in Duprat et al.24,25 and
Desmyter et al.7, while functional connectivity ﬁndings
were reported in Baeken et al.26.
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Clinical assessments
For the behavioral analyses, patients were assessed with
the self-rating Beck Scale for Suicidal Ideation (BSI) and
the Beck Depression Inventory (BDI-I) at each time point
during the study (T1, T2, T3, and T4). The BDI assesses
the severity of symptoms of depression in terms of how
patients felt over the previous week, while the BSI mea-
sures the current intensity of suicidal ideations, inten-
tions, and plans.
aiTBS stimulation protocol
We applied accelerated intermittent TBS stimulation
using a Magstim Rapid2 Plus1 magnetic stimulator
(Magstim Company Limited, Wales, UK) with an active
and a sham 70-mm Double Air Film ﬁgure-of-eight
shaped cooled coil. The Magstim 70-mm Double Air Film
sham coil is identical to its active variant, in that it is
identical in all aspects but without stimulation output. By
stimulating the peripheral nerves of the face and scalp, the
Air Film sham coil looks, sounds, and feels the same as an
active coil, both to the subject and operator but it does
not deliver active stimulation of deep nerves (https://
www.magstim.com/product/43/70mm-double-air-ﬁlm-
sham-coil). To accurately target the left DLPFC, we used
Brainsight neuronavigation (Brainsight™, Rogue Resolu-
tions, Inc) to locate the center part of the midprefrontal
gyrus. The 20 iTBS sessions were spread over 4 days at
ﬁve sessions per day, mounting a total of 32.400 stimuli
(see Fig. 1 for a full overview, and Duprat et al.24 for more
details). During each session, patients received 1620 pul-
ses per session in 54 triplet bursts with a train duration of
2 s, and an intertrain interval of 8 s (from start to end and
including the 2 s train duration). Between two sessions,
there was a pause of ~15min. Throughout the whole
aiTBS treatment (active and sham), patients were blind-
folded, ﬁtted with earplugs, and were kept unaware of the
type of stimulation they received. A stimulation intensity
of 110% of the subject’s resting motor threshold (rMT)
was maintained throughout the treatment.
Brain imaging
The scans were performed on a Siemens 3-T TrioTim
MRI scanner (Siemens, Erlangen, Germany) with a 32
channel SENSE head coil. To obtain individual anatomical
information, all subjects underwent a ﬁrst T1-weighted
MRI (3D-TFE, TR/TE= 2530/2.58; ﬂip angle= 7° FOV=
220 × 220 mm2; resolution= 0.9 × 0.9 × 0.9 mm³ number
of slices= 176) of the brain. For every individual, we
Fig. 1 Flowchart of the experimental aiTBS treatment protocol. After a washout period, all TRD (treatment-resistant depressed) patients were at
least 2 weeks antidepressant (AD) free before they underwent the ﬁrst Arterial Spin Labeling (ASL1) scan at time T1 (on a Monday morning). Hereafter,
patients were randomly divided into two groups to receive 20 sessions of real or sham aiTBS treatment, respectively. Line AB= a TRD patient who
ﬁrst received active aiTBS now receives sham; line BA= a patient who ﬁrst received sham treatment now receives active aiTBS. This treatment was
spread over the four succeeding afternoons (ﬁve daily sessions on Tuesday, Wednesday, Thursday, and Friday). In the second week, strictly the same
treatment schedule was followed but with a change of stimulation. A second ASL scan was performed exactly 1 week after the ﬁrst week (time T2)
and a third ASL scan exactly after 2 weeks (time T3), always on a Monday morning. Before the start of every time point (T1, T2, and T3), suicide and
depression severity symptoms were assessed with the 21-item Beck Scale for Suicidal Ideation (BSI) and the 21-item Beck Depression Inventory (BDI-I).
Patients were clinically re-assessed after two weeks at T4 with the, however, without ASL scan. However, for this ASL study these delayed T4
measurements were not used as well as the last ASL 3 scan at T3 in patients having received ﬁrst active treatment, depicted in the dotted line white
block
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located the left DLPFC visually on the 3D surface ren-
dering of the brain based on the known gyral morphology
and marked the center part of the midprefrontal gyrus as
the left DLPFC target (Brodmann 9/46).
Multi-delay pulsed arterial spin-labeled (pASL) images
with a 3D GRASE readout were obtained with the fol-
lowing parameters: TR= 3.4 s, TE= 14.46 ms, labeling
duration= 1400ms, post-labeling delay changing from
300 to 3000 ms in steps of 300ms, resulting in 12 pairs of
slice-selective (SS) and non-selective (NS) images, scan
duration= 5.26 min. This scanning procedure was repe-
ated three times: ASL1 at baseline, ASL2 after the ﬁrst
week of aiTBS, ASL3 after the second week of aiTBS (see
Fig. 1). During the ASL measurements, patients were
asked to stay awake with their eyes closed.
Data analysis
Behavioral data
All behavioral data were analyzed using SPSS 24 (IBM,
Statistical Package for the Social Sciences, Chicago, IL,
USA). The signiﬁcance level was set at p<0.05, two-tailed,
for all analyses.
Imaging data
The pASL and anatomical images were pre-processed
and analyzed using FSL (FMRIB, Oxford, UK) and SPM12
(Wellcome Trust Centre for Neuroimaging, London, UK).
The individual structural images were segmented into
gray matter, white matter, and cerebrospinal ﬂuid with
SPM12. All NS and SS images were realigned to the mean
image to correct for motion (using 4th-degree B-spline
interpolation in SPM12). The mean image was afﬁne-
registered to the anatomical image, and the resulting
warps were applied to the realigned images with SPM12.
Then, 12 perfusion-weighted images were generated by
surround subtraction, i.e., the differences between the
paired SS and NS images. The perfusion-weighted images
were submitted for CBF estimation using Oxford ASL
(oxford_asl) tool in FSL. The partial volume effects in
generated CBF maps were corrected by a regression
algorithm in PETPVE12 toolbox27 (https://github.com/
GGonEsc/petpve12). Finally, the generated CBF maps
were spatially normalized into MNI space and smoothed
with Gaussian kernel (8-mm full-width half-maximum).
First, to evaluate the inﬂuence of the initial severities of
suicidal ideation on whole-brain perfusion, the baseline
ASL maps (ASL1) were used in a multiple regression
analysis, with the baseline ASL scans (ASL1), and the
baseline BSI scores at T1 as the regressors, while cor-
recting for age and gender. Because we were interested in
the placebo effects of aiTBS on suicidal ideation, the
signiﬁcant surviving clusters were used as mask for the
following regression analyses.
Second, to examine the relation between the change in
perfusion and the change in BSI scores after the ﬁrst week
of aiTBS stimulation (T1–T2) separately for the group
having received ﬁrst active or sham treatment, we calcu-
lated the changes in perfusion between the baseline ASL
scan and the second ASL scan, 3 days after the last aiTBS
session (delta ASL=ASL1–ASL2). Gender, age, and the
changes in depression severity (delta BDI= BDI1–BDI2)
and suicidal ideation (delta BSI= BSI1–BSI2) were the
covariates, while the change in perfusion (delta ASL=
ASL1–ASL2) was the dependent variable. The change in
depression severity was added as a co-variate because of
the documented placebo responses in rTMS studies,
including active stimulation13.
Third, to directly contrast the relation between the
change in perfusion and the change in BSI scores between
the group receiving sham versus active aiTBS in the ﬁrst
week (between subject analysis), we calculated the chan-
ges in perfusion between the baseline ASL scan and the
second ASL scan, 3 days after the last aiTBS session (delta
ASL=ASL1–ASL2). Gender, age, and the changes in
depression severity (delta BDI= BDI1–BDI2) and suicidal
ideation (delta BSI= BSI1–BSI2) were the covariates,
while the change in perfusion (delta ASL=ASL1–ASL2)
was the dependent variable.
Fourth, to examine the question whether the change in
perfusion in relation to changes in BSI scores changed
after the crossover from sham to active aiTBS, we also
calculated the changes in perfusion between the second
ASL scan and the third and last ASL scan (delta ASL=
ASL2–ASL3) in the group of 24 patients receiving ﬁrst
sham aiTBS in the ﬁrst week and active aiTBS in the
second week (within subjects). Gender, age, and the
changes in depression severity (delta BDI= BDI2–BDI3),
and suicidal ideation (delta BSI= BSI2–BSI3) were the
covariates. The change in perfusion (delta ASL=
ASL2–ASL3) was the dependent variable.
For all ASL analyses, we applied the AlphaSim correc-
tion of p<0.05 as implemented in the REST toolbox 1.8
(restfmri.net/forum/), smoothness was estimated for all
statistical maps, 1000 iterations). Corresponding brain
regions were identiﬁed with the Talairach Daemon
(search range: nearest gray matter) implemented in WFU
PickAtlas28.
Results
Behavioral results
Twenty-one MDD patients received active iTBS treat-
ment in the ﬁrst week and sham stimulation in the second
week. Twenty-four patients followed the reverse order
(see Table 1). Given the intention-to-treat aiTBS protocol,
we used a last-observation-carry-forward approach. There
were no signiﬁcant order differences in gender
(χ2(45)= 0.16, p= 0.69), age (U= 211.500, n1= 24,
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n2= 21, p= 0.36), the number of comorbidities
(U= 194.000, n1= 24, n2= 21, p= 0.17), baseline BSI
(U= 246.500, n1= 24, n2= 21, p= 0.90), and baseline
BDI (U= 224.500, n1= 24, n2= 21, p= 0.52). Baseline
BDI and BSI scores correlated signiﬁcantly (rs= 0.31,
n= 45, p= 0.04).
Wilcoxon-paired T tests showed that 4 days of sham
aiTBS resulted in a signiﬁcant decrease in BSI scores (z=
−2.24, n-ties= 19, p= 0.03), while 4 days of active aiTBS
resulted in a borderline-signiﬁcant decrease in BSI scores
(z=−1.89, n-ties= 14, p= 0.06). The change in BSI
scores (delta BSI week 1= BSI2–BSI1) after 1 week of
active stimulation (median= 0.00, IR= 7.50) was not
signiﬁcantly differed from the change after 1 week of
sham aiTBS (median= 2.50, IR= 7.50; U= 224.500, n1=
24, n2= 21, p= 0.53). The change in BSI scores (delta BSI
week 2= BSI3–BSI2) during the second week after active
stimulation (median= 0.00, IR= 1.50; z=−1.32, n-ties
= 14, p= 0.19) was not signiﬁcantly different from the
change after sham stimulation (median= 0.00, IR= 3.75;
z=−1.37, n-ties= 14, p= 0.17; U= 230.500, n1= 24,
n2= 21, p= 0.62).
ASL results
First, the whole-brain regression analysis revealed two
large positive regression clusters between baseline perfu-
sion (ASL1) and the individual BSI (T1) scores in the
superior frontal gyrus (Brodmann area (BA) 10: k= 1933
voxels: MNI coordinates: x=−6, y= 72, z=−3) and in
the caudate (k= 1528 voxels: MNI coordinates: x= 12, y
=−24, z= 24). This means that the higher the individual
BSI scores at baseline the higher the perfusion in these
areas. The minimum k was 850 voxels after AlphaSim
correction at p<0.05; see Fig. 2a and Table 2a).
Second, the 24 TRD patients who received sham aiTBS
in the ﬁrst week (within subjects sham only; between T1
and T2) showed a signiﬁcant positive association between
the change in suicidal ideation (delta BSI= BSI1–BSI2)
and the change in perfusion (delta ASL=ASL1–ASL2) in
the bilateral frontal cortices (BA 10). This means that a
decrease in perfusion after the ﬁrst week of sham stimu-
lation was associated with a decrease in suicidal ideation,
while perfusion increases correlated with a worsening of
suicidal ideation. The 21 TRD who received active aiTBS
during the ﬁrst week (within subjects active only; between
T1 and T2) showed no signiﬁcant positive or negative
associations between perfusion changes (delta ASL=
ASL1–ASL2) and BSI changes (delta BSI= BSI1–BSI2)
(p<0.05, AlphaSim corrected; see Fig. 2b and Table 2b).
Third, compared with the group having had 1 week of
active aiTBS treatment (n= 21), the group having
received 1 week of placebo aiTBS (n= 24) (between
subject analysis, active > sham iTBS) showed signiﬁcant
decreases in brain perfusion (delta ASL=ASL1–ASL2) inT
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the superior frontal gyrus after placebo stimulation (BA
10: k= 111 voxels: MNI coordinates: x= 6, y= 72, z= 15)
associated with signiﬁcant decreases in suicidal ideation
(delta BSI= BSI1–BSI2). The minimum k was 39 voxels
after AlphaSim correction at p<0.05 (see Fig. 2b and Table
2c). This indicates that the improvement or worsening of
suicidal ideation especially in the sham condition is
mediated by these prefrontal cortices.
Fourth, focusing on the group of 24 patients receiving
sham aiTBS in the ﬁrst week and active aiTBS in the
second week (within subjects; sham= > active crossover
group, between T2 and T3; focussing on delta ASL=
ASL2–ASL3 and delta BSI= BSI2–BSI3), showed no sig-
niﬁcant surviving regression clusters within the regions of
interest (p<0.05, AlphaSim corrected). This suggests that
the placebo effect on perfusion patterns is especially
present in the ﬁrst week (sham; T1–T2) and not any more
in the second week of aiTBS treatment (active; T2–T3; see
Table 2d.
Discussion
This study shows that aiTBS treatment decreases sui-
cidal ideation within 4 days of stimulation, whether active
or sham. Our ﬁndings also indicate that suicidal ideation
is primarily attenuated during the ﬁrst week and not
signiﬁcantly further during the second week of aiTBS
treatment. Remarkably, and as reported in Desmyter
et al.7, this decrease in suicidal ideation lasts up to
1 month after baseline measurements (i.e., to the ﬁnal
behavioral assessment), also in patients who do not
respond to this intervention in terms of a decrease in
depressive symptoms. Brain imaging shows that higher
baseline levels of suicidal ideation are associated with
higher perfusion patterns in brain areas overlapping with
the default mode network (DMN), particularly in the right
Fig. 2 Sagittal, axial, and coronal views of the signiﬁcant regression baseline ASL x BSI. See Table 2 for full details
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hemisphere, and in the caudate. After 4 days of stimula-
tion with sham, aiTBS perfusion decreases are found in
the bilateral frontopolar cortices (BA 10), part of the
DMN, and this is associated with a decrease in suicidal
ideation. Importantly, these changes in suicidal ideation
and perfusion are not related to a change in the severity of
symptoms of depression.
Preceding a discussion of these ﬁndings in terms of their
contribution to the understanding and prevention of
suicide, a few methodological issues need to be addressed.
Major advantages of the current study include the neu-
ronavigated coil localization of the left DLPFC and the use
of a sham 70-mm Double Air Film ﬁgure-of-eight shaped
cooled coil that is identical to its active variant but
Table 2 Regression analyses
(A) Cluster size (⌗voxels) Anatomical region Hemisphere BA T-value df Peak coordinates (x, y, z)
(mm)
Baseline ASL1 BSI T1
Positive 1933 Superior frontal gyrus Left 10 4.46 1,41 −6, 72, –3
Superior frontal gyrus Right 10 4.34 1,41 24, 69, –3
Orbitofrontal cortex Right 11 4.15 1,41 24, 69, 0
Superior frontal gyrus Right 10 3.94 1,41 27, 66, –12
Supramarginal gyrus Right 40 3.26 1,41 42, –45, 57
Dorsolateral prefrontal cortex Right 9 3.31 1,41 60, 18, 27
1528 Caudate Right – 3.76 1,41 12, –24, 24
Inferior parietal lobule Left 40 3.32 1,41 −33, –51, 33
Supramarginal gyrus Left 40 3.02 1,41 −45, –42, 45
Somatosensory association
cortex
Left 7 2.80 1,41 −24, –69, 33
Precuneus Right – 2.65 1,41 12, –51, 57
Negative No signiﬁcant clusters emerged
(B) Delta ASL (T1–T2) Delta BSI (T1–T2)
Active
Positive No signiﬁcant clusters
emerged
Negative No signiﬁcant clusters
emerged
Sham
Positive 258 Superior frontal gyrus Right 10 3.87 1, 19 30, 66, –6
162 Middle frontal gyrus Left 10 3.63 1, 19 −39, 60, 0
Negative No signiﬁcant clusters emerged
(C) Delta ASL (T1–T2) Delta BSI (T1–T2)
(between subjects)
Active > sham
Sham > active 111 Superior frontal gyrus Right 10 4.29 1,38 6, 72, 15
(D) Delta ASL * (T1–T2) vs.
(T2–T3)
Delta BSI (T1–T2) vs.
(T2–T3)
(within subjects)
Active>sham No signiﬁcant clusters emerged
Sham>active No signiﬁcant clusters emerged
*Only those 24 TRD patients having received ﬁrst sham aiTBS in the ﬁrst week (T1–T2) before the crossover to real aiTBS treatment in the second week (T2–T3)
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without stimulation output. Nevertheless, all interpreta-
tions should be limited to antidepressant-free treatment-
resistant depressed patients. Furthermore, we only
examined one aspect of possible placebo aiTBS effects on
the brain, namely cerebral perfusion. In addition, we can
only conclude a decrease on suicidal ideation in a
depressed but not highly suicidal group of patients, where
suicide attempts within the last 6 months were an
exclusion criterion. Lastly, although patients were naive to
the iTBS procedure in their ﬁrst week of stimulation
(between T1 and T2), in the second week were only those
patients who had received ﬁrst sham treatment, in their
second week of active aiTBS (between T2 and T3), carry-
over effects or blinding issues may have interfered with
the perfusion ﬁndings.
Given the fact that a number of ﬁndings are similar to
those of previous studies, the impact of these limitations
appears to be limited. Georges et al.5 showed that high-
dose left prefrontal sham and active rTMS results in
prompt decreases in suicidal ideation during a 3-day
protocol. The imaging ﬁndings showing cerebral corre-
lates of suicidal ideation are in keeping with those from
previous studies of suicidal ideation and behavior. The
99mTc HMPAO SPECT imaging study of Amen et al.29
showed signiﬁcantly higher perfusion in the right hemi-
sphere when suicidal depressed patients were compared
with a non-suicidal depressed group. In vivo and post-
mortem neurobiological studies point at the involvement
of the DMN, ventromedial and parietal regions, and the
caudate area in increased suicide risk30–38.
The involvement of the frontopolar cortex, commonly
referred to as “Brodmann area 10”, is of particular interest.
This part of the prefrontal cortex is proportionally larger
in volume relative to the rest of the human brain39. The
frontopolar cortex is involved in higher cognitive func-
tions, especially in the integration of executive functions
and cognitive ﬂexibility. Impairments in cognitive ﬂex-
ibility are linked with suicidal ideation and behavior40.
Post-mortem studies examining BA 10 of individuals who
died by suicide show increased levels of proinﬂammatory
cytokines in teenagers, reduced levels of BDNF in female
suicides, and increased levels of neuropeptides, including
CRH in male and female suicides35. Neurostimulation
techniques, such as electroconvulsive therapy (also known
for its prompt anti-suicidal effects) and deep brain sti-
mulation targeting the nucleus accumbens, have also been
found to result in frontopolar glucose metabolism
decreases in treatment-resistant depressed patients41,42.
Brain lesions, located in the ventromedial parts, are
associated with markedly low levels of depression and
lower scores on cognitive/affective symptoms of depres-
sion (such as guilt, self-dislike, and sadness), and possibly
suicidal ideation43. While beneﬁcial placebo effects of
antidepressant pharmacotherapy on depressive symptoms
are well established12, such effects on suicidal ideation are
much less clear. A large clinical study among depressed
patients, comparing psychotherapy and medication
treatments to placebo, showed no differences after
adjustment for change in symptoms of depression44.
Diminished severity of depression may thus drive reduc-
tions in suicidal ideation during antidepressant treatment,
whether active or placebo. To study the placebo effect of
aiTBS, the change in severity of depression was therefore
added as a co-variate in the brain perfusion analyses in the
current study.
The reduced frontopolar perfusion after sham aiTBS
after 4 days of stimulation in the current study is in line
with placebo-induced brain responses found in other
pathologies, i.e., reduced pain-related brain activations
during placebo analgesia, often correlated with psycho-
physical pain measures9,15. The involvement of BA 10 in
response to painful events suggests that this frontopolar
cortical area plays a critical role in the collation, integra-
tion, and high-level processing of nociception and pain45.
As reductions in BA 10 perfusion were coupled with
decreases in suicidal ideation in the current study, these
ﬁndings may indicate changes in higher cognitive pro-
cesses involving the formation of expectations46, but also
self-referential thinking and appraisal, such as value pro-
cessing16. Here, “value” is deﬁned as an appraisal of the
gain or cost (economic, social, or physical) for current and
future well-being, made about the self and in considera-
tion of one’s goals. Frontopolar perfusion decreases after
sham aiTBS suggest that MDD patients re-appraise their
current situation more positively and consequently feel
less suicidal. Of interest, the stimulated area (the left
DLPFC) has also repeatedly been shown to be involved in
the processing of placebo effects9. Indeed, the major
direct synaptic projections to the frontopolar cortex ori-
ginate in higher-order association areas, such as the
DLPFC47,48. The DLPFC may also be involved in main-
taining and updating expectancies that drive the placebo
effect by modulating cortico-subcortical and corticocor-
tical pathways49. On the other hand, sham-induced pla-
cebo effects on perfusion patterns as seen after the initial
sham aiTBS were not observed after the crossover from
active to sham aiTBS treatment. This may be due to carry-
over effects, but also suggests that placebo responses to
accelerated rTMS paradigms already occur at an early
stage in this treatment protocol.
The lack of signiﬁcant brain perfusion alterations in
relation to suicidal ideation changes after active aiTBS is
surprising. This could suggest a lack of effect of active
aiTBS on suicidal ideation, but it could also indicate that
the underlying neurobiological mechanisms of action in
promptly reducing negative thinking patterns after active
neurostimulation could be quite different from mechan-
isms involved in sham responses. This latter
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interpretation is supported by ﬁndings from a resting state
fMRI study in the same sample as used in the current
study: the decrease in the severity of symptoms of
depression and the levels of hopelessness after active
aiTBS, but not after sham stimulation, was associated with
stronger functional connectivity between the subgenual
anterior cingulate cortex and the medial orbitofrontal
cortex. These cortical areas both are involved in cognitive
inhibition and depressive rumination26.
In conclusion, the current study ﬁndings indicate that
sham aiTBS rapidly attenuates suicidal ideation in
treatment-resistant depressed patients, while signiﬁcantly
reducing brain perfusion in the frontopolar cortex. Sham
aiTBS may lead to a more positive appraisal of the current
situation and thus to a reduction in suicidal ideation. It
remains to be demonstrated whether or not these placebo
effects are limited to accelerated rTMS paradigms. Future
rTMS studies in depression should consider targeting the
frontopolar cortical regions more directly, especially when
suicidal ideation is present.
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